Paradigm Spine
http://www.paradigmspine.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Paradigm Spine
CureVac Frames Comeback With Dutch Biotech Buy
The German firm is buying Frame Cancer Therapeutics in a deal valued at €32m, with CEO Franz-Werner Haas claiming that it will help the firm in its search for promising neoantigens for its mRNA cancer vaccine programs.
Deal Watch: Kite Inks Novel AML Target Discovery Tie-Up With HiFiBiO
Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.
Vertiflex Superion Spacer Panel Reset To Give FDA More Review Time
FDA's Orthopaedics and Rehabilitation Devices Panel had planned to consider Vertiflex's PMA for its Superion interspinous spacer device on Dec. 12, but the agency postponed the meeting to Feb. 20 give it more time to review device information.
Vertiflex’s Superion Interspinous Spacer Gets FDA Panel Date
FDA’s Orthopaedic and Rehabilitation Devices Panel will meet in December to consider Vertiflex’s submission to support approval of the Superion interspinous spacer to treat moderate lumbar spinal stenosis.
Company Information
- Industry
- Medical Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice